436 related articles for article (PubMed ID: 26332672)
1. Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials.
Huang Y; Follmann D; Nason M; Zhang L; Huang Y; Mehrotra DV; Moodie Z; Metch B; Janes H; Keefer MC; Churchyard G; Robb ML; Fast PE; Duerr A; McElrath MJ; Corey L; Mascola JR; Graham BS; Sobieszczyk ME; Kublin JG; Robertson M; Hammer SM; Gray GE; Buchbinder SP; Gilbert PB
PLoS One; 2015; 10(9):e0136626. PubMed ID: 26332672
[TBL] [Abstract][Full Text] [Related]
2. Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study.
Gray GE; Moodie Z; Metch B; Gilbert PB; Bekker LG; Churchyard G; Nchabeleng M; Mlisana K; Laher F; Roux S; Mngadi K; Innes C; Mathebula M; Allen M; McElrath MJ; Robertson M; Kublin J; Corey L;
Lancet Infect Dis; 2014 May; 14(5):388-96. PubMed ID: 24560541
[TBL] [Abstract][Full Text] [Related]
3. Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine.
Gray G; Buchbinder S; Duerr A
Curr Opin HIV AIDS; 2010 Sep; 5(5):357-61. PubMed ID: 20978374
[TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa.
Jaoko W; Karita E; Kayitenkore K; Omosa-Manyonyi G; Allen S; Than S; Adams EM; Graham BS; Koup RA; Bailer RT; Smith C; Dally L; Farah B; Anzala O; Muvunyi CM; Bizimana J; Tarragona-Fiol T; Bergin PJ; Hayes P; Ho M; Loughran K; Komaroff W; Stevens G; Thomson H; Boaz MJ; Cox JH; Schmidt C; Gilmour J; Nabel GJ; Fast P; Bwayo J
PLoS One; 2010 Sep; 5(9):e12873. PubMed ID: 20877623
[TBL] [Abstract][Full Text] [Related]
5. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial.
Buchbinder SP; Mehrotra DV; Duerr A; Fitzgerald DW; Mogg R; Li D; Gilbert PB; Lama JR; Marmor M; Del Rio C; McElrath MJ; Casimiro DR; Gottesdiener KM; Chodakewitz JA; Corey L; Robertson MN;
Lancet; 2008 Nov; 372(9653):1881-1893. PubMed ID: 19012954
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study.
Gray GE; Allen M; Moodie Z; Churchyard G; Bekker LG; Nchabeleng M; Mlisana K; Metch B; de Bruyn G; Latka MH; Roux S; Mathebula M; Naicker N; Ducar C; Carter DK; Puren A; Eaton N; McElrath MJ; Robertson M; Corey L; Kublin JG;
Lancet Infect Dis; 2011 Jul; 11(7):507-15. PubMed ID: 21570355
[TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity of the Merck adenovirus serotype 5 (MRKAd5) and MRKAd6 human immunodeficiency virus type 1 trigene vaccines alone and in combination in healthy adults.
Harro C; Sun X; Stek JE; Leavitt RY; Mehrotra DV; Wang F; Bett AJ; Casimiro DR; Shiver JW; DiNubile MJ; Quirk E;
Clin Vaccine Immunol; 2009 Sep; 16(9):1285-92. PubMed ID: 19605598
[TBL] [Abstract][Full Text] [Related]
8. Continued Follow-Up of Phambili Phase 2b Randomized HIV-1 Vaccine Trial Participants Supports Increased HIV-1 Acquisition among Vaccinated Men.
Moodie Z; Metch B; Bekker LG; Churchyard G; Nchabeleng M; Mlisana K; Laher F; Roux S; Mngadi K; Innes C; Mathebula M; Allen M; Bentley C; Gilbert PB; Robertson M; Kublin J; Corey L; Gray GE
PLoS One; 2015; 10(9):e0137666. PubMed ID: 26368824
[TBL] [Abstract][Full Text] [Related]
9. A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204).
Churchyard GJ; Morgan C; Adams E; Hural J; Graham BS; Moodie Z; Grove D; Gray G; Bekker LG; McElrath MJ; Tomaras GD; Goepfert P; Kalams S; Baden LR; Lally M; Dolin R; Blattner W; Kalichman A; Figueroa JP; Pape J; Schechter M; Defawe O; De Rosa SC; Montefiori DC; Nabel GJ; Corey L; Keefer MC;
PLoS One; 2011; 6(8):e21225. PubMed ID: 21857901
[TBL] [Abstract][Full Text] [Related]
10. Safety and Immunogenicity of a rAd35-EnvA Prototype HIV-1 Vaccine in Combination with rAd5-EnvA in Healthy Adults (VRC 012).
Crank MC; Wilson EM; Novik L; Enama ME; Hendel CS; Gu W; Nason MC; Bailer RT; Nabel GJ; McDermott AB; Mascola JR; Koup RA; Ledgerwood JE; Graham BS;
PLoS One; 2016; 11(11):e0166393. PubMed ID: 27846256
[TBL] [Abstract][Full Text] [Related]
11. A study of vaccine-induced immune pressure on breakthrough infections in the Phambili phase 2b HIV-1 vaccine efficacy trial.
Hertz T; Logan MG; Rolland M; Magaret CA; Rademeyer C; Fiore-Gartland A; Edlefsen PT; DeCamp A; Ahmed H; Ngandu N; Larsen BB; Frahm N; Marais J; Thebus R; Geraghty D; Hural J; Corey L; Kublin J; Gray G; McElrath MJ; Mullins JI; Gilbert PB; Williamson C
Vaccine; 2016 Nov; 34(47):5792-5801. PubMed ID: 27756485
[TBL] [Abstract][Full Text] [Related]
12. Novel adenovirus vector-based vaccines for HIV-1.
Barouch DH
Curr Opin HIV AIDS; 2010 Sep; 5(5):386-90. PubMed ID: 20978378
[TBL] [Abstract][Full Text] [Related]
13. A phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-Uninfected East Africans (RV 172).
Kibuuka H; Kimutai R; Maboko L; Sawe F; Schunk MS; Kroidl A; Shaffer D; Eller LA; Kibaya R; Eller MA; Schindler KB; Schuetz A; Millard M; Kroll J; Dally L; Hoelscher M; Bailer R; Cox JH; Marovich M; Birx DL; Graham BS; Michael NL; de Souza MS; Robb ML
J Infect Dis; 2010 Feb; 201(4):600-7. PubMed ID: 20078213
[TBL] [Abstract][Full Text] [Related]
14. Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study).
Duerr A; Huang Y; Buchbinder S; Coombs RW; Sanchez J; del Rio C; Casapia M; Santiago S; Gilbert P; Corey L; Robertson MN;
J Infect Dis; 2012 Jul; 206(2):258-66. PubMed ID: 22561365
[TBL] [Abstract][Full Text] [Related]
15. Fc Gamma Receptor Polymorphisms Modulated the Vaccine Effect on HIV-1 Risk in the HVTN 505 HIV Vaccine Trial.
Li SS; Gilbert PB; Carpp LN; Pyo CW; Janes H; Fong Y; Shen X; Neidich SD; Goodman D; deCamp A; Cohen KW; Ferrari G; Hammer SM; Sobieszczyk ME; Mulligan MJ; Buchbinder SP; Keefer MC; DeJesus E; Novak RM; Frank I; McElrath MJ; Tomaras GD; Geraghty DE; Peng X
J Virol; 2019 Nov; 93(21):. PubMed ID: 31434737
[TBL] [Abstract][Full Text] [Related]
16. Immune-correlates analysis of an HIV-1 vaccine efficacy trial reveals an association of nonspecific interferon-γ secretion with increased HIV-1 infection risk: a cohort-based modeling study.
Huang Y; Duerr A; Frahm N; Zhang L; Moodie Z; De Rosa S; McElrath MJ; Gilbert PB
PLoS One; 2014; 9(11):e108631. PubMed ID: 25369172
[TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of adenovirus-vectored near-consensus HIV type 1 clade B gag vaccines in healthy adults.
Harro CD; Robertson MN; Lally MA; O'Neill LD; Edupuganti S; Goepfert PA; Mulligan MJ; Priddy FH; Dubey SA; Kierstead LS; Sun X; Casimiro DR; DiNubile MJ; Shiver JW; Leavitt RY; Mehrotra DV;
AIDS Res Hum Retroviruses; 2009 Jan; 25(1):103-14. PubMed ID: 19108693
[TBL] [Abstract][Full Text] [Related]
18. Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine.
Hammer SM; Sobieszczyk ME; Janes H; Karuna ST; Mulligan MJ; Grove D; Koblin BA; Buchbinder SP; Keefer MC; Tomaras GD; Frahm N; Hural J; Anude C; Graham BS; Enama ME; Adams E; DeJesus E; Novak RM; Frank I; Bentley C; Ramirez S; Fu R; Koup RA; Mascola JR; Nabel GJ; Montefiori DC; Kublin J; McElrath MJ; Corey L; Gilbert PB;
N Engl J Med; 2013 Nov; 369(22):2083-92. PubMed ID: 24099601
[TBL] [Abstract][Full Text] [Related]
19. Mucosal trafficking of vector-specific CD4+ T lymphocytes following vaccination of rhesus monkeys with adenovirus serotype 5.
Masek-Hammerman K; Li H; Liu J; Abbink P; La Porte A; O'Brien KL; Whitney JB; Carville A; Mansfield KG; Barouch DH
J Virol; 2010 Oct; 84(19):9810-6. PubMed ID: 20686023
[TBL] [Abstract][Full Text] [Related]
20. Chimeric adenovirus type 5/35 vector encoding SIV gag and HIV env genes affords protective immunity against the simian/human immunodeficiency virus in monkeys.
Someya K; Xin KQ; Ami Y; Izumi Y; Mizuguchi H; Ohta S; Yamamoto N; Honda M; Okuda K
Virology; 2007 Oct; 367(2):390-7. PubMed ID: 17628628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
